A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
研究单位：[1]Janssen Research & Development, LLC[2]University of California at San Diego,La Jolla,California,United States,92093[3]University of California, Irvine,Orange,California,United States,92868[4]Stanford Cancer Institute,Stanford,California,United States,94305[5]Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital,Washington,District of Columbia,United States,20016[6]Baptist Lynn Cancer Institute,Boca Raton,Florida,United States,33486[7]Mount Sinai Medical Center,Miami Beach,Florida,United States,33140[8]AdventHealth,Orlando,Florida,United States,32804[9]H. Lee Moffitt Cancer & Research Institute,Tampa,Florida,United States,33612[10]University of Kansas Cancer Center,Westwood,Kansas,United States,66205[11]Boston Medical Center,Boston,Massachusetts,United States,02118[12]Washington University School of Medicine,Saint Louis,Missouri,United States,63110[13]Hackensack University Medical Center,Hackensack,New Jersey,United States,07601[14]Rutgers Cancer Institute of New Jersey,New Brunswick,New Jersey,United States,08901[15]Hemotology Oncology Associates of CNY,East Syracuse,New York,United States,13057[16]Novant Health,Charlotte,North Carolina,United States,28204[17]Novant Health,Winston-Salem,North Carolina,United States,27106[18]Cleveland Clinic,Cleveland,Ohio,United States,44111[19]Cleveland Clinic,Cleveland,Ohio,United States,44195[20]Cleveland Clinic,Mayfield Heights,Ohio,United States,44124[21]Cleveland Clinic,Warrensville Heights,Ohio,United States,44122[22]The Huntsman Cancer Institute,Salt Lake City,Utah,United States,84112[23]Virginia Cancer Specialists,Fairfax,Virginia,United States,22031[24]Swedish Cancer Institute,Seattle,Washington,United States,98104[25]Fundacao Pio XII,Barretos,Brazil,14784-400[26]PERSONAL - Oncologia de Precisão e Personalizada,Belo Horizonte,Brazil,30130 090[27]Instituto do Cancer de Londrina - Hospital do Cancer de Londrina,Londrina,Brazil,86015[28]Associacao Hospitalar Moinhos de Vento,Porto Alegre,Brazil,90035-001[29]Instituto D'Or de Pesquisa e Ensino (IDOR),Rio de Janeiro,Brazil,22281-100[30]Instituto D'Or de Pesquisa e Ensino (IDOR),Salvador,Brazil,41253-190[31]Impar Servicos Hospitalares SA - Hospital Nove de Julho,Sao Paulo,Brazil,01409-001[32]Fundacao Antonio Prudente - A.C. Camargo Cancer Center,Sao Paulo,Brazil,01509900[33]Hospital Alemao Oswaldo Cruz,São Paulo,Brazil,01327-001[34]Affiliated Hospital of Hebei University,Baoding,China,71000[35]Jilin cancer hospital,Changchun,China,130000[36]Sichuan Cancer Hospital,Chengdu,China,610041[37]West China Hospital, Sichuan University,Chengdu,China,610047[38]Southwest Hospital,ChongQing,China,400038[39]The First Affiliated Hospital, Sun Yat-sen University,Guangzhou,China,510060[40]The First Affiliated Hospital Zhejiang University College of Medicine,Hangzhou,China,310003[41]Sir Run Run Shaw Hospital, Zhejiang University School of Medicine,Hangzhou,China,310016[42]Harbin medical university cancer hospital,Harbin,China,150081[43]Huizhou Municipal Central Hospital,Huizhou,China,516001[44]Liuzhou people's Hospital,Liuzhou,China,545006[45]Fudan University Shanghai Cancer Center,Shanghai,China,200032[46]Tianjin Medical University General Hospital,Tianjin,China,300052[47]The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China,325000[48]Union Hospital Tongji Medical College of Huazhong University of Science and Technology,Wuhan,China,430022[49]Hospital of Jiangnan University,Wuxi,China,214122[50]The First Affiliated Hospital of Xi'an Jiaotong University,XI An,China,710061
研究目的：
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation [SC-CF]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).
